PL2569009T3 - Chimery ospa i ich zastosowanie do szczepień - Google Patents

Chimery ospa i ich zastosowanie do szczepień

Info

Publication number
PL2569009T3
PL2569009T3 PL11722243T PL11722243T PL2569009T3 PL 2569009 T3 PL2569009 T3 PL 2569009T3 PL 11722243 T PL11722243 T PL 11722243T PL 11722243 T PL11722243 T PL 11722243T PL 2569009 T3 PL2569009 T3 PL 2569009T3
Authority
PL
Poland
Prior art keywords
vaccines
ospa chimeras
ospa
chimeras
Prior art date
Application number
PL11722243T
Other languages
English (en)
Inventor
Brian A. Crowe
Ian Livey
Maria O'rourke
Michael Schwendinger
Original Assignee
Baxalta Incorporated
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Incorporated, Baxalta GmbH filed Critical Baxalta Incorporated
Publication of PL2569009T3 publication Critical patent/PL2569009T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11722243T 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie do szczepień PL2569009T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
EP11722243.0A EP2569009B1 (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines
PCT/US2011/036525 WO2011143617A1 (en) 2010-05-14 2011-05-13 Chimeric ospa genes, proteins, and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2569009T3 true PL2569009T3 (pl) 2020-06-15

Family

ID=44121257

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11720967T PL2569008T3 (pl) 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie w szczepionkach
PL11722243T PL2569009T3 (pl) 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie do szczepień

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11720967T PL2569008T3 (pl) 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie w szczepionkach

Country Status (13)

Country Link
US (6) US8623375B2 (pl)
EP (4) EP2569008B1 (pl)
JP (6) JP6030052B2 (pl)
KR (7) KR102130584B1 (pl)
CN (3) CN103108652B (pl)
AU (2) AU2011252850B2 (pl)
BR (2) BR112012029058B1 (pl)
CA (2) CA2799181C (pl)
MX (3) MX340739B (pl)
PL (2) PL2569008T3 (pl)
RU (2) RU2636455C2 (pl)
SI (2) SI2569008T1 (pl)
WO (2) WO2011143623A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2569008T1 (sl) 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih
US8571937B2 (en) 2010-10-20 2013-10-29 Playspan Inc. Dynamic payment optimization apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
WO2013090611A2 (en) * 2011-12-13 2013-06-20 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
EP3682897A1 (en) * 2012-07-27 2020-07-22 Baxalta GmbH Compositions comprising chimeric ospa molecules and methods of use thereof
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
BR112015023500B1 (pt) * 2013-03-15 2021-01-12 The Regents Of The University Of California composição farmacêutica
WO2015041710A1 (en) * 2013-09-23 2015-03-26 Ventria Bioscience, Inc. Ospa fusion protein for vaccination against lyme disease
SMT201900383T1 (it) * 2014-01-09 2019-09-09 Valneva Austria Gmbh Frammenti mutanti di ospa e metodi e utilizzi correlati ad essi
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2016025331A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
PT3509337T (pt) * 2015-08-14 2021-08-02 Ericsson Telefon Ab L M Nó e método para gestão de uma ligação de rede de dados em pacotes
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
ES2957939T3 (es) * 2017-04-13 2024-01-30 Valneva Austria Gmbh Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos
CA3095175A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic respiratory syncytial virus polypeptides
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
CN112584858A (zh) * 2018-04-03 2021-03-30 赛诺菲 抗原性ospa多肽
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
CN115698044A (zh) * 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
MX2023007135A (es) 2020-12-17 2023-08-25 Idexx Lab Inc Detección y tratamiento de la fiebre de las montañas rocosas.
WO2022261050A1 (en) * 2021-06-07 2022-12-15 The University Of Massachusetts Apparatus and method for continuous production of rna
CA3244889A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US6143872A (en) 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0536335A4 (en) 1990-06-15 1993-07-14 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0571538B1 (en) 1991-02-15 1998-07-08 The Uab Research Foundation Structural gene of pneumococcal protein
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
EP0877085A1 (en) 1991-08-15 1998-11-11 SMITHKLINE BEECHAM BIOLOGICALS s.a. OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
CA2175567C (en) 1993-11-01 2010-08-10 John J. Dunn Chimeric proteins comprising borrelia polypeptides: uses therefor
DK0880360T3 (da) 1996-02-12 2003-01-27 Ml Lab Plc Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
CA2294701C (en) * 1997-06-30 2009-09-08 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
DK1311540T3 (da) 2000-08-18 2008-04-28 Brookhaven Sciences Ass Llc Ændret OspA af Borrelia Burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
AU2001281145A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Recombinant constructs of borrelia burgdorferi
ATE420887T1 (de) 2003-04-02 2009-01-15 Us Gov Health & Human Serv Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi
JP2006525330A (ja) * 2003-04-16 2006-11-09 ワイエス・ホールディングス・コーポレーション 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
CA2560487C (en) * 2004-03-24 2013-01-29 Merck & Co., Inc. Optimized expression of hpv 52 l1 in yeast
EP1768688A4 (en) 2004-07-02 2009-09-30 Raymond J Dattwyler ORAL BORRELIOSE VACCINE
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1957520A4 (en) 2005-11-29 2009-05-27 Univ Virginia Commonwealth POLYVALENTIC CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
AU2007295927A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
AU2008217189B2 (en) 2007-02-22 2013-06-13 Baxalta GmbH Method of purification of hydrophobic proteins
PL2167121T3 (pl) * 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
MX2010007461A (es) * 2008-01-11 2010-10-20 VGX Pharmaceuticals LLC Nuevas vacunas contra multiples subtipos del virus del dengue.
WO2009131665A1 (en) 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
SI2569008T1 (sl) * 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih
EP3682897A1 (en) * 2012-07-27 2020-07-22 Baxalta GmbH Compositions comprising chimeric ospa molecules and methods of use thereof

Also Published As

Publication number Publication date
CN107641151A (zh) 2018-01-30
KR20130062954A (ko) 2013-06-13
EP3705133A2 (en) 2020-09-09
CN107641151B (zh) 2021-10-01
CN103118701A (zh) 2013-05-22
CN103118701B (zh) 2017-10-24
US20110293652A1 (en) 2011-12-01
RU2012153972A (ru) 2014-06-20
MX2012013261A (es) 2013-04-19
BR112012029058B1 (pt) 2022-03-29
KR20200084062A (ko) 2020-07-09
JP2018150386A (ja) 2018-09-27
JP2013529077A (ja) 2013-07-18
JP6965417B2 (ja) 2021-11-10
US9895434B2 (en) 2018-02-20
RU2012153752A (ru) 2014-06-20
JP2016171816A (ja) 2016-09-29
AU2011252850A1 (en) 2012-11-29
AU2011252844B2 (en) 2014-07-03
MX348113B (es) 2017-05-29
BR112012027315A8 (pt) 2020-09-01
JP2016168057A (ja) 2016-09-23
SI2569008T1 (sl) 2020-02-28
CA2799181C (en) 2023-10-24
US9303073B2 (en) 2016-04-05
RU2583289C2 (ru) 2016-05-10
EP2569008B1 (en) 2019-12-25
KR20130133120A (ko) 2013-12-06
US20140141030A1 (en) 2014-05-22
WO2011143617A1 (en) 2011-11-17
US11305000B2 (en) 2022-04-19
EP3705133A3 (en) 2021-01-06
BR112012029058A2 (pt) 2020-06-23
US20120020973A1 (en) 2012-01-26
US8623376B2 (en) 2014-01-07
JP6227407B2 (ja) 2017-11-08
JP6030052B2 (ja) 2016-11-24
BR112012027315B1 (pt) 2021-08-17
KR102085465B1 (ko) 2020-03-05
EP3705133B1 (en) 2024-06-26
EP2569009B1 (en) 2019-10-09
US20140141029A1 (en) 2014-05-22
KR102230562B1 (ko) 2021-03-22
BR112012027315A2 (pt) 2016-11-16
CN103108652B (zh) 2016-05-11
KR102222869B1 (ko) 2021-03-04
KR20190027955A (ko) 2019-03-15
MX375965B (es) 2025-03-07
CN103108652A (zh) 2013-05-15
KR102130584B1 (ko) 2020-07-07
US8623375B2 (en) 2014-01-07
EP2569009A1 (en) 2013-03-20
CA2798331A1 (en) 2011-11-17
KR20200024354A (ko) 2020-03-06
AU2011252850B2 (en) 2016-03-17
MX340739B (es) 2016-07-22
CA2798331C (en) 2022-03-15
US20180296656A1 (en) 2018-10-18
EP3650041A1 (en) 2020-05-13
KR20180031814A (ko) 2018-03-28
US20160235830A1 (en) 2016-08-18
US9334311B2 (en) 2016-05-10
RU2017138652A3 (pl) 2021-03-15
CA2799181A1 (en) 2011-11-17
PL2569008T3 (pl) 2021-04-19
SI2569009T1 (sl) 2020-02-28
EP2569008A1 (en) 2013-03-20
KR20180082633A (ko) 2018-07-18
RU2636455C2 (ru) 2017-11-23
JP2020178719A (ja) 2020-11-05
JP2013529078A (ja) 2013-07-18
MX2012013264A (es) 2014-12-05
AU2011252844A1 (en) 2012-11-29
WO2011143623A1 (en) 2011-11-17
RU2017138652A (ru) 2019-02-11

Similar Documents

Publication Publication Date Title
PL2569009T3 (pl) Chimery ospa i ich zastosowanie do szczepień
IL249669B (en) Converted 5-fluoro-h1-pyrazolopyridines and their use
PT2539326T (pt) Ariltriazolonas ligadas a bisaril e sua utilização
ZA201305076B (en) Substituted 1-benzylccloalkycarboxlic acids and use thereof
ZA201208173B (en) Peptices and their use
IL215389A0 (en) Pneumococcal vaccine and uses thereof
GB0922165D0 (en) Human interface device and related methods
PL2606120T3 (pl) Ludzkie komórki ułatwiające tolerancję i ich zastosowanie
ZA201300930B (en) St-246 liquid formulations and methods
ZA201302168B (en) Electrode unit for use in a fryer and fryer comprising a said electrode unit
PL2521445T3 (pl) Preparat i jego zastosowanie
ZA201304235B (en) Oprf/i agents and their use in hospitalized and other patients
SI2552440T1 (sl) Nove kombinacije in uporaba
PT2563806E (pt) Leucolectinas humanas e suas utilizações
GB201006479D0 (en) Garment and use thereof
GB201008286D0 (en) Device and use
GB201005441D0 (en) Improvements in wheelchairs
ZA201206667B (en) Improvements in and relating to implements
GB201001170D0 (en) Novel peptides and their use in therepy and diagnosis
GB201021105D0 (en) Improvements in and relating to parathas
TWM402679U (en) Portable pillow
GB201022018D0 (en) Improvements in fluid collection devices